Valvular & structural heart disease

Osteosarcopenia and Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement

JAMA CardiolPublished Post hoc analysis of the FRAILTY-AVR prospective cohort study

Primary result · 1-year mortalityResult — go to the resultOdds ratio 3.18 95% CI 1.54–6.57

Authors' conclusion

The findings suggest that osteosarcopenia detected using clinical CT scans could be used to identify frail patients with a 3-fold increase in 1-year mortality following TAVR.

Study context

Population
Patients aged ≥70 years undergoing transcatheter aortic valve replacement (TAVR), 2012–2022271 [45%] female
Participants
605 patients
Comparison
Osteosarcopenia vs low psoas muscle area (PMA) alone vs low vertebral bone density (VBD) alone vs normal bone and muscle status
  • Osteosarcopenian = 91
Primary endpoint
All-cause mortality
Follow-up
1 year
Methodological detailsmulticentre, 14 centres in Canada, US and France, McGill extension
  • Multicentre
  • 14 centres in Canada, US and France
  • McGill extension

Primary result

1-year mortality

Odds ratio

3.18

95% CI 1.54–6.57

Events by treatment group

Osteosarcopeniavs Normal bone and muscle status
OR 3.18 (95% CI 1.54–6.57)

As reported in the abstract

Difference in 1-year mortality across the four groups
P < 0.001

Secondary outcomes

OutcomeOR (95% CI)
1-year worsening disabilityOsteosarcopeniavs Normal bone and muscle statusMultivariable-adjusted2.11 (1.19–3.74)

Original publication

Osteosarcopenia and Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement. JAMA Cardiol. Published 1 July 2024. doi:10.1001/jamacardio.2024.0911

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.